Using the 6-min walk test to assess the clinical response to mepolizumab and conventional therapy in severe eosinophilic asthma.

ERJ Open Res · 2023 · PMC10588793 · PMID 37868145

Europe PMC DOI

hedged sentence

0.0790

closest p · 1.6× alpha

0.0790

boldest claim

The sentences

a trend towards significancep=0.079so close (0.05 < p ≤ 0.1)

There was also a significant difference for the Borg dyspnoea scale before treatment and a trend towards significance after treatment (p=0.079) for the patients treated with mepolizumab.

also in 2,760 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.